Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Intacoxia 90 mg Tablets
Intacoxia is formulated with Etoricoxib, a potent and selective COX-2 inhibitor designed to manage pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Each tablet contains 90 mg of Etoricoxib, providing targeted relief from discomfort and inflammation while being easier on the stomach compared to traditional NSAIDs.
Uses of Intacoxia 90 mg Tablets
Osteoarthritis: Effective in managing pain and inflammation associated with osteoarthritis.
Rheumatoid Arthritis: Provides relief from pain and inflammation in rheumatoid arthritis.
Ankylosing Spondylitis: Alleviates symptoms of ankylosing spondylitis, a type of arthritis that affects the spine.
Acute Pain Relief: Can be used for the short-term relief of acute pain conditions.
Benefits of Intacoxia 90 mg Tablets
Effective Pain Relief: Provides substantial relief from pain associated with various inflammatory conditions.
Reduced Inflammation: Helps in reducing inflammation, leading to improved mobility and function.
Fewer Gastrointestinal Issues: Selective COX-2 inhibition reduces the risk of gastrointestinal side effects commonly seen with traditional NSAIDs.
Long-Lasting Effect: Offers sustained relief from symptoms, allowing for better management of chronic conditions.
Improved Quality of Life: By alleviating pain and inflammation, Intacoxia helps in enhancing overall quality of life and daily functioning.
Mechanism of Action of Intacoxia 90 mg Tablets
Etoricoxib: Etoricoxib selectively inhibits the COX-2 enzyme, which plays a key role in the production of inflammatory prostaglandins. By specifically targeting COX-2, Intacoxia reduces the production of these inflammatory mediators while sparing COX-1, which protects the gastrointestinal lining. This selective inhibition results in effective pain relief and reduction of inflammation with a lower risk of gastrointestinal complications compared to non-selective NSAIDs.